Does PRALSETINIB Cause Myelosuppression? 33 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 33 reports of Myelosuppression have been filed in association with PRALSETINIB (Gavreto). This represents 2.3% of all adverse event reports for PRALSETINIB.
33
Reports of Myelosuppression with PRALSETINIB
2.3%
of all PRALSETINIB reports
2
Deaths
21
Hospitalizations
How Dangerous Is Myelosuppression From PRALSETINIB?
Of the 33 reports, 2 (6.1%) resulted in death, 21 (63.6%) required hospitalization, and 2 (6.1%) were considered life-threatening.
Is Myelosuppression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PRALSETINIB. However, 33 reports have been filed with the FAERS database.
What Other Side Effects Does PRALSETINIB Cause?
Death (126)
Fatigue (104)
Asthenia (96)
Off label use (92)
Hypertension (89)
Disease progression (85)
Anaemia (80)
Diarrhoea (79)
Pyrexia (75)
White blood cell count decreased (74)
What Other Drugs Cause Myelosuppression?
CYCLOPHOSPHAMIDE (3,603)
CARBOPLATIN (2,624)
TRASTUZUMAB (2,552)
PACLITAXEL (2,522)
TISLELIZUMAB (2,142)
CYTARABINE (1,869)
VENETOCLAX (1,864)
CISPLATIN (1,849)
BEVACIZUMAB (1,744)
SODIUM (1,696)
Which PRALSETINIB Alternatives Have Lower Myelosuppression Risk?
PRALSETINIB vs PRAMIPEXOLE
PRALSETINIB vs PRAMIPEXOLE\PRAMIPEXOLE
PRALSETINIB vs PRAMLINTIDE
PRALSETINIB vs PRASTERONE
PRALSETINIB vs PRASUGREL